Merck & Co
Latest statistics and disclosures from Merck & Co's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PSNL, MRNA, KYMR, AKTS, EIKN, and represent 93.25% of Merck & Co's stock portfolio.
- Added to shares of these 3 stocks: TRDA (+$13M), STRO (+$9.0M), EVAX.
- Started 3 new stock positions in TRDA, STRO, EVAX.
- Reduced shares in these 4 stocks: Entrada Therapeutics (-$22M), Sutro Biopharma (-$6.8M), Evaxion Biotech A S America, CARM.
- Sold out of its positions in CARM, Entrada Therapeutics, Evaxion Biotech A S America, Sutro Biopharma.
- Merck & Co was a net seller of stock by $-7.7M.
- Merck & Co has $526M in assets under management (AUM), dropping by 50.64%.
- Central Index Key (CIK): 0000310158
Tip: Access up to 7 years of quarterly data
Positions held by Merck & Co consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Merck & Co
Merck & Co holds 13 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Personalis Ord (PSNL) | 35.8 | $188M | 14M | 13.40 |
|
|
| Moderna (MRNA) | 30.7 | $162M | 2.3M | 70.03 |
|
|
| Kymera Therapeutics (KYMR) | 16.8 | $89M | 772k | 114.67 |
|
|
| Aktis Oncology (AKTS) | 5.8 | $31M | 953k | 32.23 |
|
|
| Eikon Therapeutics (EIKN) | 4.1 | $22M | 1.7M | 13.05 |
|
|
| Entrada Therapeutics (TRDA) | 2.4 | $13M | NEW | 1.7M | 7.36 |
|
| Sutro Biopharma (STRO) | 1.7 | $9.0M | NEW | 272k | 33.20 |
|
| Alector (ALEC) | 1.4 | $7.1M | 3.5M | 2.01 |
|
|
| Evaxion Biotech A/s Sponsored Ads (EVAX) | 0.7 | $3.8M | NEW | 1.2M | 3.10 |
|
| Miragen Therapeutics (VRDN) | 0.3 | $1.7M | 93k | 18.37 |
|
|
| Xilio Therapeutics (XLO) | 0.2 | $1.0M | 106k | 9.58 |
|
|
| Tuhura Biosciences (HURA) | 0.0 | $46k | 19k | 2.34 |
|
|
| Neuphoria Therapeutics (NEUP) | 0.0 | $44k | 10k | 4.37 |
|
Past Filings by Merck & Co
SEC 13F filings are viewable for Merck & Co going back to 2025
- Merck & Co 2026 Q2 filed Aug. 7, 2026
- Merck & Co 2026 Q1 filed May 13, 2026
- Merck & Co 2025 Q4 filed Feb. 17, 2026
- Merck & Co 2025 Q3 filed Nov. 12, 2025
- Merck & Co 2025 Q2 filed Aug. 13, 2025